KR20180088226A - Composition comprising ginseng flower extracts with enhanced ginsenoside content - Google Patents
Composition comprising ginseng flower extracts with enhanced ginsenoside content Download PDFInfo
- Publication number
- KR20180088226A KR20180088226A KR1020170013027A KR20170013027A KR20180088226A KR 20180088226 A KR20180088226 A KR 20180088226A KR 1020170013027 A KR1020170013027 A KR 1020170013027A KR 20170013027 A KR20170013027 A KR 20170013027A KR 20180088226 A KR20180088226 A KR 20180088226A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- weight
- ginseng flower
- ginsenoside
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 130
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 128
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 128
- 239000000284 extract Substances 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 229930182494 ginsenoside Natural products 0.000 title claims abstract description 28
- 229940089161 ginsenoside Drugs 0.000 title claims abstract description 21
- 241000208340 Araliaceae Species 0.000 title claims abstract 8
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 17
- 230000008591 skin barrier function Effects 0.000 claims abstract description 17
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims abstract description 14
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims abstract description 14
- 230000014509 gene expression Effects 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 230000002708 enhancing effect Effects 0.000 claims abstract description 9
- 102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 claims abstract description 7
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940030793 psoriasin Drugs 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims description 68
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 23
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 23
- 230000006837 decompression Effects 0.000 claims description 19
- 239000003960 organic solvent Substances 0.000 claims description 15
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 claims description 13
- 102000055779 human DEFB103A Human genes 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 10
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 10
- 102000049262 human DEFB4A Human genes 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 6
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 6
- -1 hBD3 Proteins 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000005194 fractionation Methods 0.000 claims description 5
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims description 5
- 101000869689 Homo sapiens Protein S100-A7 Proteins 0.000 claims description 4
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 2
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 claims description 2
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 claims description 2
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 claims description 2
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 claims description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 2
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 claims description 2
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract description 5
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 230000004888 barrier function Effects 0.000 abstract description 4
- 240000004371 Panax ginseng Species 0.000 description 122
- 230000000052 comparative effect Effects 0.000 description 30
- 239000000843 powder Substances 0.000 description 27
- 238000009472 formulation Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 239000008213 purified water Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229920002498 Beta-glucan Polymers 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 244000289527 Cordyline terminalis Species 0.000 description 4
- 235000009091 Cordyline terminalis Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000013736 caramel Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229930002875 chlorophyll Natural products 0.000 description 3
- 235000019804 chlorophyll Nutrition 0.000 description 3
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 101100274508 Oryza sativa subsp. japonica CKI1 gene Proteins 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940107131 ginseng root Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241001071864 Lethrinus laticaudis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 125000003450 decanoic acid ester group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002876 effect on osteoporosis Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000004920 epithelial cell of skin Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002786 root growth Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 명세서에는, 진세노사이드 함량이 증진된 인삼꽃 추출물을 유효성분으로 포함하는 조성물로서, 피부 장벽 기능 강화 용도를 갖는 조성물과 상기 조성물의 제조방법이 개시된다. 상기 조성물은, 피부 표면에서 항균 장벽 역할을 하는 항균 펩타이드의 유전자 hBD2, hBD3, 서리아신(psoriasin)의 발현을 증가시키므로, 피부 장벽 기능을 강화하는 효과가 있다.In this specification, a composition containing an effective ingredient of ginseng flower extract with enhanced ginsenoside content, a composition having a skin barrier function-enhancing use and a process for producing the composition are disclosed. The composition increases the expression of the genes hBD2, hBD3, and psoriasin of the antimicrobial peptide which acts as an antibacterial barrier on the skin surface, thereby enhancing the skin barrier function.
Description
본 명세서에는 진세노사이드 함량이 증진된 인삼꽃 추출물을 유효성분으로 포함하고, 피부 장벽 기능 강화 용도를 갖는 조성물과 상기 조성물의 제조방법이 개시된다.In this specification, a composition containing an effective ingredient of a ginseng flower extract having enhanced ginsenoside content and having an application for enhancing skin barrier function and a method for producing the composition are disclosed.
인삼(Panax ginseng C.A. Meyer)은 오가피과 인삼 속에 속하는 식물로서 한국, 중국 및 일본 등지에서 2,000여년 전부터 사용되어 온 생약이며, 경험적으로 질병을 예방하고 수명을 연장시킬 목적으로 사용되어 왔다. 지금까지 알려진 인삼의 효능 및 효과는 중추신경계에 대한 작용, 항발암 작용, 항암활성, 면역기능 조절작용, 항당뇨 작용, 간기능 항진효능, 심혈관 장해개선, 항동맥경화 작용, 혈압조절 작용, 갱년기 장애 개선, 골다공증에 미치는 효과, 항스트레스 및 항피로 작용, 항산화 활성 및 노화억제 효능 등이 있다.Ginseng (Panax ginseng C.A. Meyer) is a herb that belongs to the genus Ogawa and Ginseng. It has been used in Korea, China and Japan for over 2,000 years and has been used empirically to prevent disease and prolong the life span. The efficacy and effect of ginseng which has been known so far can be determined by the action of the central nervous system, the anticarcinogenic action, the anticancer activity, the immune function regulating action, the anti-diabetic action, the hyperfunction of liver function, the improvement of cardiovascular disorder, Improvement of disorder, effect on osteoporosis, anti-stress and anti-fatigue action, antioxidant activity and anti-aging effect.
인삼의 대표적 생리활성 성분인 진세노사이드(Ginsenoside)는 인삼의 지상 및 지하부에 고르게 분포되어 있으며, 특히 인삼근(뿌리), 인삼잎 및 인삼열매 등 부위에 따라 진세노사이드 함량뿐만 아니라 조성도 다른 것으로 알려져 있다.Ginsenoside, which is a representative physiologically active ingredient of ginseng, is distributed evenly on the ground and underground of ginseng. Especially, ginsenoside (root), ginseng leaf and ginseng berries have not only ginsenoside content but also composition .
최근 천연 화장품에 대한 소비자의 관심이 증대되고 동시에 한방 소재를 활용하는 많은 화장품들이 출시되면서 인삼도 화장품의 중요한 피부효능을 가진 식물소재로 연구되고 있으나, 대부분 인삼근을 이용한 추출물 또는 인삼근의 진세노사이드 성분과 인삼다당체를 활용한 것일 뿐 인삼열매와 같은 인삼의 여러 부위의 성분에 의한 효능에 대한 것은 부족한 실정이다. 이뿐 아니라, 인삼꽃은 오래 전부터 효용 가치가 알려져 있지 않고 인삼씨에 밀려 거의 폐기하는 실정이었다. 최근 인삼꽃은 특유의 신선한 향취를 지녀 향료식물로서의 가치가 주목되어 뛰어난 인삼꽃의 향취를 재현한 항료 조성물이 개발되기 시작하였다. 그러나 아직도 인삼꽃의 피부 장벽 기능 강화 등의 피부 효능에 대하여서는 알려지지 않은 상황이며 이에 대한 연구도 미흡하다.Recently, consumers are interested in natural cosmetics. At the same time, many cosmetics using herbal materials have been launched, and ginseng has been studied as a plant material having important skin effect of cosmetics. However, most of them are ginseng root extract or ginseng root ginsenoside Side effects and ginseng polysaccharides are used only. The effect of various components of ginseng such as ginseng fruit is insufficient. In addition, the value of the ginseng flower has not been known for a long time. Recently, the ginseng flower has a distinctive fresh fragrance and its value as a fragrant plant has been noted, and a fancy composition recreating the fragrance of an excellent ginseng flower has begun to be developed. However, the effect of skin barrier function of ginseng flower is still unknown, and research on it is insufficient.
한편, 인삼으로부터 추출물을 수득하는 종래의 방법은 인삼의 약리성분을 유지하면서도 세포독성을 저하시키는 데에는 부적합하다는 문제점이 있었다.On the other hand, the conventional method of obtaining an extract from ginseng has a problem in that it is inadequate to lower the cytotoxicity while maintaining the pharmacological component of ginseng.
일 측면에서, 본 발명의 목적은, 진세노사이드 Re 함량이 증진된 인삼꽃 추출물의 신규 용도를 제공하는 것이다.In one aspect, an object of the present invention is to provide a novel use of ginseng flower extract having enhanced ginsenoside Re content.
다른 측면에서, 본 발명의 목적은, 인삼꽃 추출물을 유효성분으로 포함하고 피부 장벽 기능이 강화된 조성물을 제공하는 것을 목적으로 한다.In another aspect, an object of the present invention is to provide a composition containing an extract of ginseng flower as an active ingredient and having enhanced skin barrier function.
다른 측면에서, 본 발명의 목적은, 상기 조성물의 제조방법을 제공하는 것이다.In another aspect, an object of the present invention is to provide a method for producing the composition.
일 측면에서, 본 발명은, 추출 원료인 인삼꽃의 건조물이 100 중량부일 때 진세노사이드 Re를 2.30 중량부 이상 포함하는 인삼꽃 추출물을 유효성분으로 포함하는 피부 장벽 기능 강화용 조성물을 제공한다.In one aspect, the present invention provides a composition for enhancing skin barrier function comprising, as an active ingredient, a ginseng flower extract containing ginsenoside Re in an amount of 2.30 parts by weight or more when the dried material of ginseng flower as an extraction raw material is 100 parts by weight.
다른 측면에서 본 발명은, 인삼꽃에 물, 유기용매 또는 물과 유기용매의 혼합용매를 가한 후, 가압 및 감압 추출공정을 반복적으로 실시하여 추출하는 단계를 포함하는 상기 조성물의 제조방법을 제공한다. In another aspect, the present invention provides a method for producing the composition, which comprises adding water, an organic solvent or a mixed solvent of water and an organic solvent to a ginseng flower, and repeating the step of pressurization and depressurization to extract .
일 측면에 있어서, 본 발명의 추출 원료인 인삼꽃의 건조물이 100 중량부일 때 진세노사이드 Re를 2.30 중량부 이상 포함하는 인삼꽃 추출물을 유효성분으로 포함하는 조성물은 피부 표면에서 항균 장벽 역할을 하는 항균 펩타이드의 유전자 hBD2, hBD3, 서리아신(psoriasin)의 발현을 증가시키므로, 피부 장벽 기능을 강화하는 효과가 있다.In one aspect, a composition comprising, as an active ingredient, a ginseng flower extract containing ginsenoside Re in an amount of 2.30 parts by weight or more when the dried material of the ginseng flower of the present invention is 100 parts by weight has an antimicrobial barrier It increases the expression of the genes hBD2, hBD3 and psoriasin of the antimicrobial peptide, thus enhancing the skin barrier function.
도 1은, 일반 추출 공정(대기압 조건)으로 추출된 인삼꽃 추출물(비교예 3)과
본 발명의 일 실시예에 따른 추출 공정(가압 추출 시 압력이 80MPa의 조건)으로 추출된 인삼꽃 추출물(실시예 3)의 진세노사이드의 성분을 비교 분석한 그래프이다.
도 2는, 무처리군 (대조군), 열수 추출로 추출된 인삼꽃 추출물(비교예 4), 일반 추출 공정(대기압 조건)으로 추출된 인삼꽃 추출물(비교예 3) 및 본 발명의 일 실시예에 따른 추출 공정(가압 추출 시 압력이 80MPa의 조건)으로 추출된 인삼꽃 추출물(실시예 3)의 hBD2, hBD3 및 서리아신(psoriasin) 유전자의 발현량을 확인한 도이다.FIG. 1 is a graph showing the effect of the ginseng flower extract (Comparative Example 3) extracted with the general extraction process (atmospheric pressure condition) (Comparative Example 3) and the ginseng flower extract (at the pressure of 80 MPa under pressure extraction) according to one embodiment of the present invention And the component of the ginsenoside of Example 3).
FIG. 2 is a graph showing the results of a comparison between the ginseng flower extract (Comparative Example 4) extracted with hot water extraction (Comparative Example 4), the ginseng flower extract extracted with the general extraction process (atmospheric pressure condition) (HBD2, hBD3, and psoriasin) of the ginseng flower extract (Example 3) extracted with the extraction process (pressure of 80 MPa at the time of pressurization extraction) according to the method of the present invention.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
일 측면에서, 본 발명은 추출 원료인 인삼꽃의 건조물이 100 중량부일 때 진세노사이드 Re를 2.30 중량부 이상 포함하는 인삼꽃 추출물을 유효성분으로 포함하는 피부 장벽 기능 강화용 조성물을 제공한다.In one aspect, the present invention provides a composition for enhancing skin barrier function comprising, as an active ingredient, a ginseng flower extract containing ginsenoside Re in an amount of 2.30 parts by weight or more when the dried material of ginseng flower as an extraction raw material is 100 parts by weight.
본 발명의 인삼꽃(Panax ginseng C. A. Meyer)은 인삼의 지상부에 속하며, 진세노이드 함량이 뿌리보다 많고 그 종류도 뿌리와 유사하다. 채종하지 않는 꽃은 인삼의 뿌리 성장을 촉진하기 위하여 제거된다.The ginseng flower of the present invention ( Panax ginseng CA Meyer) belongs to the above-ground part of ginseng, and its ginsenoside content is more than roots and its kind is similar to roots. The undifferentiated flowers are removed to promote root growth of ginseng.
본 발명의 진세노사이드(ginsenoside)란 글리코사이드(glycoside)의 일종인 사포닌의 한 종류로서, 식물의 뿌리, 줄기, 잎, 껍질, 씨 등에서 유래된다. 진세노사이드에는 예를 들어, 진세노사이드 Rb1, Rb2, Rc, Rd, Re, Rg1 등의 다양한 종류가 존재하며, 식물의 종류와 재배 조건, 가공 조건, 추출 방법, 인삼의 부위 등에 따라 존재하는 진세노사이드의 종류 및 함량이 달라지게 된다. 진세노사이드는 그 구조에 따라 PPT(Re, Rg1), PPD(Rb1, Rb2, Rc, Rd)로 나눌 수 있으며, Rb1, Rb2, Rc, Rd, Re 및 Rg1은 자연 인삼 그대로의 조성, 즉 홍삼화를 통한 당이 제거된 변성이 이루어지지 않은 극성의 물질로서 수용성이다.The ginsenoside of the present invention is a kind of saponin which is a kind of glycoside, and is derived from root, stem, leaf, skin, seed and the like of a plant. There are various kinds of ginsenosides, for example, ginsenosides Rb1, Rb2, Rc, Rd, Re, Rg1 and the like, and they exist depending on kinds of plants, cultivation conditions, processing conditions, The kind and content of ginsenoside are different. Rb1, Rb2, Rc, Rd, Re and Rg1 can be divided into PPT (Re, Rg1) and PPD (Rb1, Rb2, Rc and Rd) It is water-soluble as a polar substance which has not undergone denaturation by removing sugars through oxidation.
본 발명의 인삼꽃 추출물은 추출 원료인 인삼꽃의 건조물이 100 중량부일 때 진세노사이드 Re를 2.30 중량부 이상, 2.32 중량부 이상, 2.34 중량부 이상, 2.36 중량부 이상, 2.38 중량부 이상, 2.40 중량부 이상, 2.42 중량부 이상, 2.44 중량부 이상, 2.46 중량부 이상, 2.48 중량부 이상, 2.49 중량부 이상, 2.50 중량부 이상, 2.52 중량부 이상, 2.54 중량부 이상, 2.56 중량부 이상, 2.58 중량부 이상, 2.60 중량부 이상, 2.62 중량부 이상, 2.63 중량부 이상, 2.64 중량부 이상, 2.66 중량부 이상, 2.68 중량부 이상, 2.70 중량부 이상, 2.72 중량부 이상, 2.74 중량부 이상, 2.76 중량부 이상, 2.78 중량부 이상, 2.8 중량부 이상, 2.82 중량부 이상, 2.84 중량부 이상, 2.86 중량부 이상, 2.88 중량부 이상, 2.90 중량부 이상, 2.92 중량부 이상, 2.94 중량부 이상, 2.96 중량부 이상, 2.98 중량부 이상 또는 3.0 중량부 이상을 포함할 수 있다.The ginseng flower extract of the present invention contains 2.30 parts by weight or more, 2.32 parts by weight or more, 2.34 parts by weight or more, 2.36 parts by weight or more, 2.38 parts by weight or more, 2.40 parts by weight or more, 2.40 parts by weight or more, 2.42 weight parts or more, 2.44 weight parts or more, 2.46 weight parts or more, 2.48 weight parts or more, 2.48 weight parts or more, 2.49 weight parts or more, 2.50 weight parts or more, 2.52 weight parts or more, 2.54 weight parts or more, At least 2.60 parts by weight, at least 2.62 parts by weight, at least 2.63 parts by weight, at least 2.64 parts by weight, at least 2.64 parts by weight, at least 2.66 parts by weight, at least 2.68 parts by weight, at least 2.70 parts by weight, at least 2.72 parts by weight, at least 2.74 parts by weight, At least 2.78 parts by weight, at least 2.78 parts by weight, at least 2.8 parts by weight, at least 2.82 parts by weight, at least 2.84 parts by weight, at least 2.86 parts by weight, at least 2.88 parts by weight, at least 2.90 parts by weight, at least 2.92 parts by weight, at least 2.94 parts by weight, Not less than 2.98 parts by weight, or not less than 3.0 parts by weight The can be included.
본 발명의 인삼꽃 추출물은 추출 원료인 인삼꽃의 건조물이 100 중량부일 때 0.25 중량부 이상, 0.26 중량부 이상, 0.27 중량부 이상, 0.28 중량부 이상, 0.29 중량부 이상 또는 0.30 중량부 이상의 진세노이드 Rb1을 포함할 수 있고, 0.20 중량부 이상, 0.21 중량부 이상, 0.22 중량부 이상, 0.23 중량부 이상, 0.24 중량부 이상 또는 0.25 중량부 이상의 진세노이드 Rb2를 포함할 수 있으며, 또는 0.20 중량부 이상, 0.22 중량부 이상, 0.24 중량부 이상, 0.26 중량부 이상, 0.28 중량부 이상, 0.30 중량부 이상, 0.31 중량부 이상, 0.32 중량부 이상, 0.33 중량부 이상 또는 0.34 중량부 이상의 진세노이드 Rc를 포함할 수 있다. 또한, 본 발명의 인삼꽃 추출물은 추출 원료인 인삼꽃의 건조물이 100 중량부일 때 0.60 중량부 이상, 0.62 중량부 이상, 0.64 중량부 이상, 0.66 중량부 이상, 0.68 중량부 이상, 0.70 중량부 이상, 0.72 중량부 이상, 0.74 중량부 이상, 0.76 중량부 이상, 0.78 중량부 이상, 0.80 중량부 이상, 0.81 중량부 이상, 0.82 중량부 이상, 0.83 중량부 이상 또는 0.84 중량부 이상의 진세노이드 Rd를 포함할 수 있으며, 또는 0.25 중량부 이상, 0.26 중량부 이상, 0.27 중량부 이상, 0.28 중량부 이상, 0.29 중량부 이상, 0.30 중량부 이상 또는 0.31 중량부 이상의 진세노이드 Rg1을 포함할 수 있다. 본 발명의 일 실시예에 따르면, 24시간, 30℃의 물의 온도, 80MPa의 가압 추출시의 압력 및 대기압의 감압 추출시의 압력 조건 하에서 가압 및 감압 추출 공정으로 제조된 인삼꽃 추출물(실시예 1 내지 3)은 일반 추출 공정으로 제조된 인삼꽃 추출물(비교예 1 내지 3)에 비해 수율이 높고 인삼꽃 분말 100g을 기준으로 한 진세노사이드 Re의 절대량(g)이 증가하였으며, 더 많은 진세노이드를 포함하고 있음을 확인하였다(시험예 1 내지 3 및 도 1).The ginseng flower extract of the present invention contains 0.25 parts by weight or more, 0.26 parts by weight or more, 0.27 parts by weight or more, 0.28 parts by weight or more, 0.29 parts by weight or more, or 0.30 parts by weight or more of ginsenosides Rb1, and may comprise at least 0.20 parts by weight, at least 0.21 parts by weight, at least 0.22 parts by weight, at least 0.23 parts by weight, at least 0.24 parts by weight, or at least 0.25 parts by weight of ginsenoside Rb2, or at least 0.20 parts by weight 0.22 weight parts or more, 0.24 weight parts or more, 0.26 weight parts or more, 0.28 weight parts or more, 0.30 weight parts or more, 0.31 weight parts or more, 0.32 weight parts or more, 0.33 weight parts or more, or 0.34 weight parts or more of ginsenoside Rc can do. The ginseng flower extract of the present invention may contain at least 0.60 part by weight, at least 0.62 part by weight, at least 0.64 part by weight, at least 0.66 part by weight, at least 0.68 part by weight, at least 0.70 part by weight At least 0.72 part by weight, at least 0.74 part by weight, at least 0.76 part by weight, at least 0.78 part by weight, at least 0.80 part by weight, at least 0.81 part by weight, at least 0.82 part by weight, at least 0.83 part by weight or at least 0.84 part by weight of ginsenoside Rd Or 0.25 weight parts or more, 0.26 weight parts or more, 0.27 weight parts or more, 0.28 weight parts or more, 0.29 weight parts or more, 0.30 weight parts or more, or 0.31 weight parts or more of ginsenoside Rg1. According to one embodiment of the present invention, the ginseng flower extract prepared in the pressure and reduced pressure extraction process under the pressure condition at the time of extracting the pressure of 80 MPa, the pressure at 80 MPa, To 3) showed higher yields than the ginseng flower extracts prepared in the general extraction process (Comparative Examples 1 to 3), and the absolute amount (g) of ginsenoside Re was increased on the basis of 100 g of ginseng flower powder. (Test Examples 1 to 3 and Fig. 1).
본 발명의 피부 장벽(Stratum corneum, Skin barrier)은 죽은 각질세포(Coneocyte)와 세포간 지질(Intercellular lipid)로 구성되어 있고, 외부 자극으로부터 피부를 보호하며 피부에서 수분이 증발하는 것을 막아주는 피부 보호막으로서 피부건강에 핵심적인 기능을 담당한다.The skin barrier (Stratum corneum) of the present invention is composed of dead keratinocyte (intercellular lipid) and intercellular lipid. It protects the skin from external stimuli and protects the skin from evaporation of moisture. As a function of skin health.
본 발명의 항균 펩타이드는 피부 표면에서 항균 장벽과 관련 있는 항균 펩타이드로서, 항균 펩타이드 유전자의 발현량이 증가할수록 피부 장벽 기능은 더욱 강화될 수 있다. 본 발명의 항균 펩타이드 유전자는 인간 베타 디펜신 2(hBD2, human beta defensin 2), 인간 베타 디펜신 3(hBD3, human beta defensin 3) 및 서리아신(psoriasin)으로 이루어진 군으로부터 선택된 하나 이상의 유전자일 수 있다. 상기 hBD2 및 hBD3는 포유류에 있는 디펜신 패밀리(defensin family)의 한 종류로서, 베타-디펜신(Beta-defensin)은 항균펩타이드 기능을 갖고 있어 매우 많은 그람음성(Gram-negative) 혹은 그람양성(Gram-positive) 박테리아와 곰팡이균 등에 대한 저항성을 나타낸다. 상기 서리아신은 S100A7로도 알려져 있으며, S100 단백질 패밀리의 한 종류로서, 피부 상피세포에서 분비되고 침착되어 항균 장벽 형성에 기여한다. 본 발명의 일 실시예에 따르면, 24시간, 30℃의 물의 온도, 80MPa의 가압 추출시의 압력 및 대기압의 감압 추출시의 압력 조건 하에서 제조된 인삼꽃 추출물(실시예 3)을 각질형성세포에 처리 시, 무처리군(대조군), 열수 추출물(비교예 4), 및 대기압 하에서의 일반 추출 공정에 의해 제조된 추출물(비교예 3)보다 hBD2, hBD3 및 서리아신 유전자의 발현을 증가시킴을 확인하였는바, 특정 함량 이상의 진세노이드 Re를 포함하는 본 발명의 인삼꽃 추출물은 항균 펩타이드의 발현을 증가시킴으로써, 피부 장벽 기능을 강화하는 효과가 있음을 확인하였다(시험예 4 및 도 2).The antimicrobial peptide of the present invention is an antimicrobial peptide related to an antibacterial barrier on the skin surface. As the expression amount of the antimicrobial peptide gene increases, the skin barrier function can be further strengthened. The antimicrobial peptide gene of the present invention may be one or more genes selected from the group consisting of human beta defensin 2,
본 발명의 인삼꽃 추출물은 추출 원료인 인삼꽃 건조물이 100 중량부일 때 진세노사이드 Re를 2.30 중량부 이상 포함하는 인삼꽃 추출물을 제조할 수 있는 방법이라면 제한되지 않고 사용 가능하며, 가압 및 감압 추출 공정을 사용할 수 있다. 상기 가압 및 감압 추출 공정은 추출 공정 중 압력을 변화시키는 가압 공정 또는 감압 공정을 수행하는 공정일 수 있다. 구체적으로, 본 발명의 인삼꽃 추출물은 가압 공정 또는 감압 공정을 교대로 수행하는 압력 순환 추출 공정 등으로 제조할 수 있으며, 이들을 연속적으로 실시할 수도 있다. 상기 압력 순환 추출 공정은 구체적으로 인삼꽃에 물, 유기용매 또는 이들의 혼합용매를 가한 후 일정 시간마다 가압 및 감압을 반복 실시함으로써 수행될 수 있다. 보다 구체적으로, 가압 및 감압 추출공정은 18 시간 이상, 19 시간 이상, 20시간 이상, 21시간 이상, 22시간 이상, 23시간 이상, 또는 24시간 이상 동안 반복 실시될 수 있고, 30시간 이하, 29시간 이하, 28시간 이하, 27시간 이하, 26시간 이하, 25시간 이하, 또는 24시간 이하 동안 반복 실시될 수 있다. 상기 가압 및 감압 추출공정 시 추출 온도는 25℃ 이상, 26℃ 이상, 27℃ 이상, 28℃ 이상, 29℃ 이상, 또는 30℃ 이상일 수 있으며, 35℃ 이하, 34℃ 이하, 33℃ 이하, 32℃ 이하, 31℃ 이하, 또는 30℃ 이하일 수 있다. 상기 가압 추출공정 시 압력은 60MPa 이상, 65MPa 이상, 70MPa 이상, 75MPa 이상, 또는 80MPa 이상일 수 있으며, 100MPa 이하, 95MPa 이하, 90MPa 이하, 85MPa 이하, 또는 80MPa 이하일 수 있고, 감압 추출공정 시 압력은 대기압일 수 있다.The ginseng flower extract of the present invention can be used without limitation as long as it can produce ginseng flower extract containing 2.30 parts by weight or more of ginsenoside Re when the dried ginseng flower is 100 parts by weight. Process can be used. The pressurized and reduced pressure extraction process may be a process of performing a pressurization process or a depressurization process that changes the pressure during the extraction process. Specifically, the ginseng flower extract of the present invention can be produced by a pressure circulation extraction process or the like which alternately performs a pressurization process or a depressurization process, and they can be carried out continuously. Specifically, the pressure circulation and extraction process may be performed by adding water, an organic solvent or a mixed solvent thereof to the ginseng flower, and repeating the pressurization and decompression at regular intervals. More specifically, the pressurized and reduced pressure extraction process may be repeated for at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, or at least 24 hours, Hour, 28 hours or less, 27 hours or less, 26 hours or less, 25 hours or less, or 24 hours or less. The extraction temperature may be 25 ° C or higher, 26 ° C or higher, 27 ° C or higher, 28 ° C or higher, 29 ° C or higher or 30 ° C or higher, and 35 ° C or lower, 34 ° C or lower, Deg.] C, 31 [deg.] C or less, or 30 [deg.] C or less. The pressure during the pressure extraction process may be at least 60 MPa, at least 65 MPa, at least 70 MPa, at least 75 MPa, or at least 80 MPa and may be at most 100 MPa, at least 95 MPa, at least 90 MPa, at most 85 MPa, or at most 80 MPa, Lt; / RTI >
본 발명의 일 실시예에 따르면, 가장 우수한 수율 및 진세노이드 Re 절대량을 보이는 인삼꽃 추출물을 제조하기 위한 가압 및 감압 추출 공정의 최적 조건은 24 시간의 처리 시간, 30℃의 물의 온도 및 80MPa의 가압 추출시의 압력 조건임을 확인하였다(시험예 2).According to one embodiment of the present invention, the optimum conditions for the pressure and decompression extraction processes for producing the ginseng flower extract having the best yield and the absolute amount of ginsenoside Re are 24 hours of treatment time, the temperature of water at 30 ° C and the pressure of 80 MPa It was confirmed that the pressure condition at the time of extraction (Test Example 2).
본 발명의 조성물은 인삼꽃 추출물을 조성물 총 중량에 대하여 0.0001 중량% 내지 99 중량%, 구체적으로는 0.1 중량% 내지 99 중량%, 더욱 구체적으로는 1 중량% 내지 50 중량% 포함할 수 있다. The composition of the present invention may contain 0.0001 wt% to 99 wt%, specifically 0.1 wt% to 99 wt%, more specifically 1 wt% to 50 wt% of ginseng flower extract based on the total weight of the composition.
상기와 같은 측면에서, 상기 조성물은, 약학적 조성물, 화장료 조성물 또는 식품 조성물일 수 있다.In this aspect, the composition may be a pharmaceutical composition, a cosmetic composition, or a food composition.
상기 약학적 조성물은 상기 조성물을 유효성분으로 하여 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여제 혹은 비경구 투여제로 제제화할 수 있다.The pharmaceutical composition may be formulated into an oral or parenteral dosage form in the form of a solid, semi-solid or liquid form by adding an inorganic or organic carrier, which is compatible with the composition, as an active ingredient.
상기 경구 투여를 위한 제재로서는 정제, 환제, 과립제, 연, 경 캡슐제, 산제, 세립제, 분제, 유탁제, 시럽제, 펠렛제 등을 들 수 있다. 또한, 상기 비경구 투여를 위한 제재로는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제, 좌제 등을 들 수 있다. 본 발명의 유효성분을 제제화하기 위해서는 상법에 따라서 실시하면 용이하게 제제화할 수 있으며 계면활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제, 기타 상용하는 보조제를 적당히 사용할 수 있다.Examples of the agent for oral administration include tablets, pills, granules, soft capsules, powders, fine granules, powders, emulsions, syrups and pellets. Examples of the parenteral administration agent include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. In order to formulate the active ingredient of the present invention, it can be easily formulated according to the conventional method. Surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffering agents, suspending agents and other adjuvants can be suitably used.
본 발명에 따른 약학적 조성물은 피부 장벽을 강화시키는 효과가 우수하여 피부 장벽의 손상에 의해 유발되는 피부질환의 치료 및 예방에 유용하게 사용할 수 있다. 상기 피부장벽 손상에 의해 유발되는 피부질환으로는 아토피 피부염(atopic dermatitis), 피부건조증(xeroderma), 건선(psoriasis), 어린선(ichthyosis), 여드름 등이 있으나, 이에 한정되는 것은 아니다.The pharmaceutical composition according to the present invention is excellent in the effect of strengthening the skin barrier, and thus can be useful for the treatment and prevention of skin diseases caused by damage to the skin barrier. Skin diseases caused by skin barrier damage include, but are not limited to, atopic dermatitis, xeroderma, psoriasis, ichthyosis, acne and the like.
상기 약학적 조성물은 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다.The pharmaceutical composition may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously, and the like.
또한, 상기 활성성분의 투여량은 치료 받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있다. 일반적인 투여량은 0.001 mg/kg/일 내지 2000 mg/kg/일, 구체적으로는 0.5 mg/kg/일 내지 1500 mg/kg/일이다.In addition, the dosage of the active ingredient will depend on the age, sex, body weight of the subject to be treated, the particular disease or condition to be treated, the severity of the disease or condition, the route of administration and the judgment of the prescriber. Dosage determinations based on these factors are within the level of those skilled in the art. Typical dosages are from 0.001 mg / kg / day to 2000 mg / kg / day, specifically from 0.5 mg / kg / day to 1500 mg / kg / day.
상기 화장료 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있다. 예를 들면, 액, 수상에 유상을 분산시켜 얻은 에멀젼, 유상에 수상을 분산시켜 얻은 에멀젼, 현탁액, 고체, 겔, 분말, 페이스트, 포말(foam) 또는 에어로졸 조성물의 제형으로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.The cosmetic composition may be provided in all formulations suitable for topical application. For example, it may be provided as a liquid, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an oil phase in water, a suspension, a solid, a gel, a powder, a paste, a foam or an aerosol composition. Compositions of such formulations may be prepared according to conventional methods in the art.
상기 화장료 조성물은 상기한 물질 이외에 주 효과를 손상시키지 않는 범위 내에서, 구체적으로는 주 효과에 상승 효과를 줄 수 있는 다른 성분들을 함유할 수 있다. 본 발명에 따른 화장료 조성물은 비타민, 고분자 펩티드, 분자 다당 및 스핑고 지질로 이루어진 군에서 선택된 물질을 포함할 수 있다. 또한 본 발명에 따른 화장료조성물은 보습제, 에몰리언트제, 계면 활성제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 냉감제 또는 제한(制汗)제를 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 전체 중량을 기준으로 0.001 내지 5 중량%, 구체적으로 0.01 내지 3 중량%일 수 있다.The cosmetic composition may contain, in addition to the above-mentioned materials, other ingredients that do not impair the main effect, specifically, those that can give synergy to the main effect. The cosmetic composition according to the present invention may include a material selected from the group consisting of vitamins, high molecular peptides, molecular polysaccharides and sphingolipids. The cosmetic composition according to the present invention may also contain a moisturizing agent, an emollient agent, a surfactant, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjuster, an organic and inorganic pigment, a fragrance, . The blending amount of the above components can be easily selected by those skilled in the art within a range not to impair the object and effect of the present invention. The blending amount thereof can be 0.001 to 5% by weight, specifically 0.01 to 3% have.
상기와 같은 측면에서, 상기 약학적 조성물 또는 화장료 조성물은 피부 외용제 조성물일 수 있다. 예컨대, 크림, 연고일 수 있다.In the above aspect, the pharmaceutical composition or cosmetic composition may be a composition for external application to the skin. For example, it may be cream or ointment.
상기 식품 조성물은 건강 식품 조성물일 수 있으며, 다(茶)류, 유제품류, 김치류, 양조 식품류를 예로 들 수 있는 발효가 필요한 발효 식품 조성물일 수 있다. 상기 식품 조성물의 제형은 특별히 한정되지 않으나, 예를 들어, 정제, 환제, 연질 및 경질 캅셀제, 과립제, 드링크제, 캐러멜, 다이어트바, 티백 등으로 제형화될 수 있다. 각 제형의 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다. 상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 투여하고자 하는 대상의 연령, 건강 상태, 합병증 등의 다양한 요인에 따라 달라질 수 있다.The food composition may be a health food composition, and may be a fermented food composition requiring fermentation, such as tea, dairy, kimchi, and brewed foods. The formulation of the food composition is not particularly limited, but may be formulated into tablets, pills, soft and hard capsules, granules, drinks, caramels, diet bars, tea bags and the like. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients. The dosage of the active ingredient is within the level of those skilled in the art and may vary depending on various factors such as the age, health condition, complications, etc. of the subject to be administered.
다른 측면에서, 본 발명은 상기 조성물의 제조방법으로서, 인삼꽃에 1차 용매로서 물 또는 알코올을 가한 후, 가압 및 감압 추출공정을 반복적으로 실시하여 1차 추출하는 단계를 포함하는 조성물의 제조방법을 제공한다. 또한, 상기 제조방법은 상기 추출된 1차 추출물을 염소 함유 유기용매로 분획하고 염소 함유 유기용매를 층을 제거한 다음 물 층을 다시 알코올로 2차 추출하는 단계;를 추가적으로 포함하되, 상기 1차 용매가 알코올인 경우 염소 함유 유기용매로 분획 전에 1차 추출물을 물에 녹이는 것을 포함할 수 있다.In another aspect, the present invention provides a method for producing a composition comprising adding water or an alcohol as a primary solvent to a ginseng flower and then subjecting the ginseng flower to a primary extraction by repeating the pressure and vacuum extraction steps . The method may further comprise fractionating the extracted primary extract with a chlorine-containing organic solvent, removing the chlorine-containing organic solvent layer, and then extracting the water layer with alcohol again, wherein the primary solvent The alcohol may be dissolved in water before the fractionation with a chlorine-containing organic solvent.
상기 알코올은 메탄올, 에탄올, 부탄올, 프로판올 및 이소프로판올 등을 포함하는, 탄소수 1 내지 5의 저급 알코올일 수 있고, 에틸아세테이트 등의 극성용매와 헥산 또는 메틸렌 클로라이드의 비극성용매와 같은 유기용매 또는 이들의 혼합용매일 수 있다. 구체적으로, 상기 알코올은 10 내지 90 %(v/v) 에탄올, 보다 구체적으로, 80 %(v/v) 에탄올일 수 있다. 본 발명의 1차 용매는 물 또는 알코올일 수 있고, 2차 용매는 알코올일 수 있으며, 구체적으로 1차 용매는 물일 수 있고, 2차 용매는 에탄올일 수 있다.The alcohol may be a lower alcohol having 1 to 5 carbon atoms, including methanol, ethanol, butanol, propanol and isopropanol, and may be an organic solvent such as a polar solvent such as ethyl acetate and a nonpolar solvent such as hexane or methylene chloride, or a mixture thereof It can be used every day. Specifically, the alcohol may be 10 to 90% (v / v) ethanol, more specifically 80% (v / v) ethanol. The primary solvent of the present invention may be water or alcohol, and the secondary solvent may be alcohol. Specifically, the primary solvent may be water, and the secondary solvent may be ethanol.
상기 염소 함유 유기용매는 염소(클로라이드, chloride)를 함유하는 유기용매로서, 메틸렌 클로라이드(methylene chloride), 클로로포름, 염화메틸 및 사염화탄소로 이루어진 군으로부터 선택되는 하나 이상일 수 있으며, 구체적으로 메틸렌 클로라이드일 수 있다.The chlorine-containing organic solvent may be at least one selected from the group consisting of methylene chloride, chloroform, methyl chloride and carbon tetrachloride, and may be specifically methylene chloride as an organic solvent containing chlorine (chloride) .
상기 1차 용매, 2차 용매 및 염소 함유 유기용매는 서로 동일하거나 다를 수 있다.The primary solvent, the secondary solvent and the chlorine-containing organic solvent may be the same or different from each other.
상기와 같이 가압 및 감압 추출 공정을 실시할 경우, 인삼꽃의 열변성을 최소화하여 진세노사이드의 변성을 최소화할 수 있다. 따라서, 인삼꽃 추출물을 기존의 단순한 추출 장치로 가압 및 감압 없이 추출할 경우에 비하여 추출 수율을 10% 이상 향상시킬 수 있는 효과가 있다.When the pressurization and decompression extraction processes are performed as described above, the thermal denaturation of the ginseng flower can be minimized and the denaturing of the ginsenoside can be minimized. Therefore, the extraction yield of the ginseng flower extract can be improved by 10% or more compared to the case of extracting the ginseng flower without using the conventional simple extraction device.
또한, 이후 메틸렌 클로라이드와 같은 염소 함유 유기용매를 사용하여 엽록소를 제거하고 에탄올과 같은 유기용매로 물 층을 2차 추출함으로써, 진세노사이드의 함량을 극대화할 수 있는 효과가 있다. Further, thereafter, the chlorophyll is removed using a chlorine-containing organic solvent such as methylene chloride, and the water layer is secondarily extracted with an organic solvent such as ethanol, thereby maximizing the content of ginsenoside.
이하, 본 발명을 하기의 실시예 및 시험예를 통하여 설명한다. 하기 실시예 및 시험예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 발명의 범주 및 범위가 그에 의해 제한되는 것은 아니다.Hereinafter, the present invention will be described with reference to the following examples and test examples. The following examples and test examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, but the scope and scope of the present invention are not limited thereto.
[비교예] 일반 추출 공정으로 인삼꽃 추출물 제조[Comparative Example] Production of ginseng flower extract by general extraction process
[비교예 1 및 2] 일반 추출 공정으로 인삼꽃 추출물 분말 제조[Comparative Examples 1 and 2] Preparation of ginseng flower extract powder by a general extraction process
대한민국 상주 및 안동에서 각각 입수한 인삼꽃을 정제수로 세척하고 열풍 또는 자연 건조로 건조시킨 다음 분쇄하여 세말화한 인삼꽃 분말을 저온에서 보관하였다. 그 후, 상기 인삼꽃 분말 0.5kg에 10L의 물을 가한 후, 30℃에서 추출하였으며, 상기 추출액을 여과하고 고형분 50%가 될 때까지 농축하였다. 농축액의 엽록소를 제거하기 위해 메틸렌 클로라이드(methylene chloride, MC) 분획을 수행하였다. 그 후 물 층을 취득하여 80% 에탄올이 될 때까지 에탄올을 첨가하고, 당을 제거하기 위해 12시간 동안 침지시킨 후, 상기 용액을 여과하고 침전물을 폐기하였다. 그런 다음 상기 여과액에서 에탄올이 제거될 때까지 농축하여 125g의 인삼꽃 추출물 분말(비교예 1, 2)을 각각 제조하였다.Ginseng flowers obtained from Sangju and Andong, Korea were washed with purified water, dried by hot air or natural drying, and then pulverized to obtain a germinated flower powder. Thereafter, 10 L of water was added to 0.5 kg of the ginseng flower powder, and the mixture was extracted at 30 캜. The extract was filtered and concentrated to a solid content of 50%. Methylene chloride (MC) fractionation was performed to remove chlorophyll from the concentrate. The water layer was then taken, ethanol was added until it became 80% ethanol, and after dipping for 12 hours to remove sugar, the solution was filtered and the precipitate discarded. Then, the filtrate was concentrated until ethanol was removed to prepare 125 g of ginseng flower extract powder (Comparative Examples 1 and 2).
[비교예 3] 진세노사이드 분석 및 항균 펩타이드 발현 확인을 위한 일반 추출 공정에 따른 인삼꽃 추출물 제조[Comparative Example 3] Analysis of ginsenoside and production of ginseng flower extract according to a general extraction process for confirming the expression of an antibacterial peptide
인삼꽃(자경종)을 상기 비교예 1 및 2의 제조방법과 동일한 방법으로 24시간, 30℃의 물의 온도 및 대기압의 조건 하에서 125g의 인삼꽃 추출물(비교예 3)을 제조하였다.125 g of ginseng flower extract (Comparative Example 3) was prepared in the same manner as in the above Comparative Examples 1 and 2 under the conditions of 24 hours, water temperature of 30 캜 and atmospheric pressure.
[비교예 4] 항균 펩타이드 발현 확인을 위한 열수 추출에 따른 인삼꽃 추출물 제조[Comparative Example 4] Production of ginseng flower extract by hot water extraction for confirming expression of an antibacterial peptide
인삼꽃(자경종) 분말 0.5kg에 10L의 물을 가한 후, 95℃에서 추출하였으며, 상기 추출액을 여과하고 고형분 50%가 될 때까지 농축하였다. 이후 상기 비교예 1 및 2의 제조방법과 동일한 방법으로 메틸렌 클로라이드 분획, 에탄올 첨가, 여과 및 농축 등의 과정을 수행하여 125g의 인삼꽃 추출물(비교예 4)을 제조하였다.10 L of water was added to 0.5 kg of the ginseng flower (green seedling) powder, and the mixture was extracted at 95 캜. The extract was filtered and concentrated to a solid content of 50%. Then, 125 g of ginseng flower extract (Comparative Example 4) was prepared by performing methylene chloride fractionation, ethanol addition, filtration and concentration in the same manner as in the preparation methods of Comparative Examples 1 and 2 above.
[실시예] 가압 및 감압 추출 공정으로 인삼꽃 추출물 제조EXAMPLES Preparation of ginseng flower extract by pressurization and decompression extraction process
[실시예 1 및 2] 가압 및 감압 추출 공정으로 인삼꽃 추출물 분말 제조[Examples 1 and 2] Preparation of ginseng flower extract powder by pressurization and reduced pressure extraction process
대한민국 상주 및 안동에서 각각 입수한 인삼꽃을 정제수로 세척하고 열풍 또는 자연 건조로 건조시킨 다음 분쇄하여 세말화한 인삼꽃 분말을 저온에서 보관하였다. 그 후, 상기 인삼꽃 분말 0.5kg에 10L의 물을 가한 후, 압력순환형 추출장치로 가압 및 감압 추출공정을 각각 15분 동안 반복적으로 실시하면서 총 24시간 동안 추출하였다. 이때, 가압 추출시의 압력은 80MPa, 감압 추출시의 압력은 대기압으로 하였으며, 추출 온도는 30℃로 설정하였다. 상기 공정에 의해 얻어진 인삼꽃 추출물을 여과하고, 고형분 50%가 될 때까지 농축하였다. 농축액의 엽록소를 제거하기 위해 메틸렌 클로라이드(methylene chloride, MC) 분획을 수행하였다. 그 후 물 층을 취득하여 80% 에탄올이 될 때까지 에탄올을 첨가하고, 당을 제거하기 위해 12시간 동안 침지시킨 후, 상기 용액을 여과하고 침전물을 폐기하였다. 그런 다음 상기 여과액에서 에탄올이 제거될 때까지 농축하여 125g의 인삼꽃 추출물 분말(실시예 1, 2)을 각각 제조하였다.Ginseng flowers obtained from Sangju and Andong, Korea were washed with purified water, dried by hot air or natural drying, and then pulverized to obtain a germinated flower powder. Thereafter, 10 L of water was added to 0.5 kg of the ginseng flower powder, and the mixture was extracted for 24 hours with a pressure circulation type extraction device repeatedly performed for 15 minutes each under pressure and reduced pressure. At this time, the pressure during the pressure extraction was 80 MPa, the pressure during the decompression extraction was atmospheric pressure, and the extraction temperature was set at 30 ° C. The ginseng flower extract obtained by the above process was filtered and concentrated to a solid content of 50%. Methylene chloride (MC) fractionation was performed to remove chlorophyll from the concentrate. The water layer was then taken, ethanol was added until it became 80% ethanol, and after dipping for 12 hours to remove sugar, the solution was filtered and the precipitate discarded. Then, the filtrate was concentrated until the ethanol was removed to prepare 125 g of ginseng flower extract powder (Examples 1 and 2).
[실시예 3] 진세노사이드 분석 및 항균 펩타이드 발현 확인을 위한 가압 및 감압 추출 공정에 따른 인삼꽃 추출물 제조[Example 3] Analysis of ginsenoside and production of ginseng flower extract by pressurization and depressurization step for confirmation of expression of antimicrobial peptide
가압 및 감압 추출 공정에 따른 추출물의 진세노사이드를 분석하기 위해 인삼꽃(자경종)을 24시간, 30℃의 물의 온도, 80MPa의 가압 추출시의 압력 및 대기압의 감압 추출시의 압력 조건 하에서 상기 실시예 1 및 2의 제조방법과 동일한 방법으로 가압 및 감압 추출 공정에 따른 125g의 인삼꽃 추출물(실시예 3)을 제조하였다.In order to analyze the ginsenosides of the extracts obtained by the pressurization and decompression extraction processes, ginseng flowers (female seedling) were cultured for 24 hours, at a temperature of 30 ° C, at a pressure of 80 MPa under pressure, 125 g of ginseng flower extract (Example 3) according to the pressure and reduced pressure extraction steps were prepared in the same manner as in the production methods of Examples 1 and 2.
[시험예 1] 추출 공정에 따른 수율 및 진세노사이드 Re의 절대량 비교[Test Example 1] Comparison of the yield according to the extraction process and the absolute amount of ginsenoside Re
상기 수득된 인삼꽃 추출물 분말(비교예 1, 2 및 실시예 1, 2)의 HLPC 분석을 수행하였으며, 그 조건은 다음과 같다.The HLPC analysis of the obtained ginseng flower extract powder (Comparative Examples 1 and 2 and Examples 1 and 2) was carried out under the following conditions.
진세노사이드 Re HPLC 분석조건Ginsenoside Re HPLC analysis conditions
- 칼럼: CAPCELL PAK C18(SHISEIDO)- Column: CAPCELL PAK C18 (SHISEIDO)
- 검출기(측정파장): 자외부흡광광도검출기(203nm)- Detector (measuring wavelength): Ultraviolet absorptivity detector (203 nm)
- 주입량, 유량: 20uL, 1.0mL/min- Injection volume, flow rate: 20 uL, 1.0 mL / min
- 이동상: Gradient conditions for HPLC (A: D.I WATER, B: 50% BeCN)- Mobile phase: Gradient conditions for HPLC (A: D.I WATER, B: 50% BeCN)
그 결과 상기 인삼꽃 추출물 분말(비교예 1, 2 및 실시예 1, 2)의 수율 및 진세노이드 Re의 절대량(g)은 하기 표 2과 같으며, 진세노이드 Re 절대량은 인삼꽃 분말 100g을 기준으로 한다.As a result, the yields of the ginseng flower extract powder (Comparative Examples 1 and 2 and Examples 1 and 2) and the absolute amount (g) of ginsenoside Re were as shown in Table 2 below. Absolute amount of ginsenoside Re was 100 g .
(비교예 1)Changzhou ginseng
(Comparative Example 1)
(비교예 2)Andong ginseng
(Comparative Example 2)
상주인삼
(실시예 1)Pressurization and Decompression
Changzhou ginseng
(Example 1)
안동인삼
(실시예 2)Pressurization and Decompression
Andong ginseng
(Example 2)
* 진세노사이드 Re 절대량은 인삼꽃 분말 100g을 기준으로 함.* Ginsenoside Re absolute amount is based on 100 g of ginseng flower powder.
그 결과, 상기 표 2에 나타난 바와 같이, 가압 및 감압 추출 공정에 따라 추출된 인삼꽃 추출물(실시예 1 및 2)은 일반 추출 공정에 따라 추출된 동일 품종의 인삼꽃 추출물(비교예 1 및 2)에 비해 수율이 각각 11%, 10% 증가하였으며, 인삼꽃 분말 100g을 기준으로 할 때 각각 0.66g, 0.73g 증가된 진세노사이드 Re를 포함하고 있음을 확인할 수 있었다.As a result, as shown in Table 2, the ginseng flower extracts (Examples 1 and 2) extracted according to the pressurization and decompression extraction processes were the same as the ginseng flower extracts (Comparative Examples 1 and 2 ) And 11% and 10%, respectively, and the ginsenoside Re was found to contain 0.66 g and 0.73 g of ginsenoside Re based on 100 g of the ginseng flower powder.
[시험예 2] 가압 및 감압 추출 공정의 최적 조건 확인[Test Example 2] Confirmation of optimal conditions of pressurization and decompression extraction process
상기 시험예 1에서 가압 및 감압 추출 공정 시 수율 및 진세노사이드 Re의 절대량이 우수함을 확인하였는바, 최적의 가압 및 감압 추출 공정의 조건을 확인하기 위해 처리 시간, 온도 및 압력 조건을 순차적으로 변화시켜 수율 및 진세노이드 Re의 절대량(g, 인삼꽃 분말 100g 기준)을 비교하였다.It was confirmed in Test Example 1 that the yield and the absolute amount of ginsenoside Re in the pressurization and decompression extraction process were superior. In order to confirm the conditions of the optimum pressurization and decompression extraction process, the processing time, temperature and pressure conditions were sequentially changed And the absolute amount of ginsenoside Re (g, based on 100 g of ginseng flower powder) were compared.
최적의 시간 조건 확인Identify optimal time conditions
가압 및 감압 추출 공정에 따라 상기 실시예 1 및 2의 인삼꽃 추출물 분말 제조 방법과 동일한 방법으로, 30℃의 물의 온도, 80MPa의 가압 추출시의 압력 및 대기압의 감압 추출시의 압력 조건 하에서 각각 1시간, 6시간, 12시간, 24시간 동안 인삼꽃 추출물 분말을 제조하고, 상기 시험예 1과 동일한 분석 조건 하에서 HPLC 분석을 수행하였으며, 그 결과를 표 3에 나타내었다.Under the conditions of the water temperature of 30 DEG C, the pressure at the time of 80 MPa pressure extraction and the pressure at the time of extraction under reduced pressure of the atmospheric pressure, 1 < RTI ID = 0.0 > Hours, 6 hours, 12 hours, and 24 hours, and HPLC analysis was performed under the same analytical conditions as in Test Example 1. The results are shown in Table 3.
최적의 온도 조건 확인Identifying Optimum Temperature Conditions
가압 및 감압 추출 공정에 따라 상기 실시예 1 및 2의 인삼꽃 추출물 분말 제조 방법과 동일한 방법으로, 24시간, 80MPa의 가압 추출시의 압력 및 대기압의 감압 추출시의 압력 조건 하에서 물의 온도를 각각 20℃, 30℃, 40℃로 변화시키면서 인삼꽃 추출물 분말을 제조하고, 상기 시험예 1과 동일한 분석 조건 하에서 HLPC 분석을 수행하였으며, 그 결과를 표 4에 나타내었다.The water temperature was measured under the pressure conditions at the time of pressure extraction at 80 MPa and the pressure at the time of extraction under reduced pressure of atmospheric pressure in the same manner as in the methods of preparing the ginseng flower extract powder of Examples 1 and 2, , 30 ° C. and 40 ° C., and the HLPC analysis was carried out under the same analytical conditions as in Test Example 1, and the results are shown in Table 4.
최적의 압력 조건 확인Identify optimal pressure conditions
가압 및 감압 추출 공정에 따라 상기 실시예 1 및 2의 인삼꽃 추출물 분말 제조 방법과 동일한 방법으로, 24시간, 30℃의 물의 온도, 대기압의 감압 추출시의 압력 조건 하에서 각각 가압 추출시의 압력을 대기압(대조군, 비교예 1 및 2의 인삼꽃 추출물 제조 시의 일반 추출 공정과 동일), 10MPa, 20MPa, 40MPa, 80MPa로 변화시키면서 인삼꽃 추출물 분말을 제조하고, 상기 시험예 1과 동일한 분석 조건 하에서 HPLC 분석을 수행하였으며, 그 결과를 표 5에 나타내었다.The pressure at the time of pressure extraction was measured in the same manner as in the methods for preparing the ginseng flower extract powder of Examples 1 and 2 under the pressure and decompression extraction processes under the conditions of 24 hours, 30 ° C water temperature, The ginseng flower extract powder was prepared by varying the atmospheric pressure (the same as in the general extraction process in preparation of the ginseng flower extract of Comparative Examples 1 and 2), 10 MPa, 20 MPa, 40 MPa and 80 MPa, HPLC analysis was performed, and the results are shown in Table 5.
그 결과, 상기 표 3 내지 5에서 나타난 바와 같이, 24 시간, 30℃의 물의 온도 및 80MPa의 가압 추출시의 압력 조건 하에서 가장 우수한 수율 및 진세노이드 Re 절대량을 보임을 확인할 수 있었다.As a result, as shown in Tables 3 to 5, it was confirmed that the best yield and the absolute amount of ginsenoside Re were observed under the pressure condition at the time of 24 hours, 30 ° C water temperature and 80 MPa pressure extraction.
[시험예 3] 진세노사이드 분석[Test Example 3] Analysis of ginsenoside
상기 시험예 2에서 가압 및 감압 추출 공정의 최적 조건을 확인하였는바, 가압 및 감압 추출 공정에 따른 추출물의 진세노사이드를 분석하기 위해 일반 추출 공정으로 제조된 인삼꽃 추출물(비교예 3)과 가압 및 감압 추출 공정으로 제조된 인삼꽃 추출물(실시예 3)의 진세노사이드 함량을 분석하였다.The optimum conditions of the pressurization and decompression extraction processes in Test Example 2 were confirmed. To examine the ginsenosides of the extract according to the pressurization and decompression extraction processes, the ginseng flower extract prepared in the general extraction process (Comparative Example 3) And the ginsenoside content of the ginseng flower extract (Example 3) prepared by the reduced pressure extraction process were analyzed.
상기 비교예 3 및 실시예 3의 인삼꽃 추출물을 상기 시험예 1과 동일한 분석 조건 하에서 HPLC 분석을 수행하고, 그 결과를 도 1에 나타내었다. 그리고 이 결과로부터 상기 인삼꽃 추출물에 함유된, 진세노사이드의 각 성분별 절대량(g, 인삼꽃 분말 100g 기준)을 하기 표 6에 나타내었다.The ginseng flower extracts of Comparative Examples 3 and 3 were subjected to HPLC analysis under the same analytical conditions as in Test Example 1, and the results are shown in FIG. From these results, the absolute amount (g, based on 100 g of ginseng flower powder) of each component of ginsenoside contained in the ginseng flower extract is shown in Table 6 below.
(비교예 3)General extraction
(Comparative Example 3)
(실시예 3)Pressurization and Decompression Extraction
(Example 3)
그 결과, 상기 표 6에 나타난 바와 같이, 가압 및 감압 추출 공정에 따른 인삼꽃 추출물(실시예 3)이 일반 추출 공정에 따른 인삼꽃 추출물(비교예 3)보다 각 진세노사이드를 약 30 내지 112% 이상 더 많이 포함하고 있음을 확인할 수 있었다. 또한, 인삼꽃 추출물에 포함된 진세노사이드의 총 중량도 실시예 3이 비교예 3보다 현저히 높은 수치를 가지고 있음을 확인할 수 있었다.As a result, as shown in Table 6, the ginseng flower extract (Example 3) according to the pressurization and decompression extraction process contained about 30 to 112 ginsenoside in the ginseng flower extract (Comparative Example 3) % More than the others. It was also confirmed that the total weight of ginsenosides contained in the ginseng flower extract was significantly higher than that of Comparative Example 3.
[시험예 4] 항균 펩타이드 유전자의 발현 확인[Test Example 4] Expression of Antibacterial Peptide Gene
상기 시험예 2의 최적 조건 하에서 제조된 인삼꽃 추출물이 항균 펩타이드 유전자의 발현에 미치는 영향을 확인하기 위해 하기와 같이 실험을 수행하였다. 실험에서 발현을 확인한 항균 펩타이드 유전자는 hBD2(human beta defensin 2), hBD3(human beta defensin 3) 및 서리아신(psoriasin)이다.In order to confirm the effect of the ginseng flower extract prepared under the optimum conditions of Test Example 2 on the expression of the antimicrobial peptide gene, the following experiment was conducted. The antimicrobial peptide genes identified in the experiment are hBD2 (human beta defensin 2), hBD3 (human beta defensin 3) and psoriasin.
각질형성세포를 KGM-gold(Lonza, #00192151) 배지를 이용하여 성장시킨 후에, 6웰 플레이트에 25,000개의 각질형성세포를 넣어주고 24시간 동안 배양하였다. 인삼꽃의 95℃ 열수추출물(비교예 4), 대기압 하 일반 추출 공정에 의한 추출물(비교예 3), 가압 시의 압력이 80MPa인 가압 및 감압 추출물(실시예 3)을 배지에 40ppm 이 되도록 희석시킨 후, 각질형성세포에 처리하였다. 이 때, 대조군에는 아무 것도 처리하지 않았다(무처리군). 24시간 동안 반응시킨 다음, RNA를 추출하기 위해 세포에 트리졸 1mL씩 넣어주고, 상온에서 5분간 균질화시켰다. 1.5mL 튜브에 옮기고, 여기에 클로로포름을 0.1mL씩 넣은 다음, 손으로 15초간 흔들어 섞어주고, 상온에서 15분간 반응시킨 후, 4℃, 13,000rpm에서 15분간 원심분리 하였다. 투명한 상층액 0.4mL을 새 튜브에 옮기고, 이소프로필 알코올을 0.5mL 넣고, 손으로 15초간 흔들어 섞어주고, 상온에서 8분간 반응시킨 후, 4℃, 13,000rpm에서 8분간 원심분리 하였다. 펠렛만 남기고 상층액은 버린 다음, 75% 알코올을 0.5mL씩 넣고, 4℃, 10,000rpm에서 5분간 원심분리 하였다. 펠렛만 남기고 상층액은 버린 다음, 탈이온수를 22μL씩 넣어 순수한 RNA를 녹였다. 스펙트로미터 기기를 이용하여 260nm 흡광도 측정으로 RNA 양을 정량한 다음, cDNA를 합성하기 위해 RNA 4μg, 10x RT 버퍼 (Invitrogen, #18080-051) 3.5μL, 50μM 올리고 dT 2μL, 0.1M DTT 3.5μL, 25mM MgCl2 7μL, 10mM dNTP 3μL, RNAaseOutTM 1μL, Superscript III 1μL을 섞어주었다. 그럼 다음, 35μL이 되도록 나머지 양을 탈이온수로 넣어주었다. PCR 기기를 이용하여 50℃에서 60분간 RT 반응을 진행하였다. 만들어진 cDNA 혼합액 35μL에 탈이온수 165μL를 넣어 총 200μL로 희석하였다. Real-time qPCR을 진행하기 위해 cDNA혼합액 5μL, 탈이온수 4μL, Taqman 2X Universal PCR Master Mix (ABI, #4304437) 10μL, Taqman primer (대조군 유전자; RPLP0, 실험군 유전자; hBD2, hBD3, psoriasin) 1μL씩을 섞어주어 총 20μL를 맞춘 다음, 96 웰 PCR tube의 각 웰마다 상기 용액을 넣어주고 Real-time PCR 장비(ABI, 모델명: 7500fast)에 로딩하였다. 리액션 셋업은 다음과 같다. 1. 홀딩단계: 95℃(10분), 2. 싸이클링단계: 95℃(15초) 및 60℃(60초), 총 40 싸이클을 반복한다. 이 때 사용된 Taqman 프라이머는 리포터역할 형광분자 FAM, ?처 NFQ-MGB 로 구성된 상용 프라이머를 이용하였으며, hBD2, hBD3, psoriasin 유전자의 발현량을 비교한 결과를 도 2에 나타내었다.After keratinocytes were grown using KGM-gold (Lonza, # 00192151) medium, 25,000 keratinocytes were added to a 6-well plate and cultured for 24 hours. (Comparative Example 4), extracts obtained by a general extraction process under atmospheric pressure (Comparative Example 3), pressurized and decompressed extracts with a pressure of 80 MPa (Example 3) were diluted to 40 ppm in the medium And then treated with keratinocytes. At this time, nothing was treated in the control group (untreated group). After reacting for 24 hours, 1 mL of trisole was added to the cells to extract RNA, and homogenized at room temperature for 5 minutes. The mixture was transferred to a 1.5-mL tube, and 0.1 mL of chloroform was added thereto. The mixture was shaken for 15 seconds by hand, allowed to react at room temperature for 15 minutes, and then centrifuged at 13,000 rpm for 15 minutes at 4 ° C. 0.4 mL of the transparent supernatant was transferred to a new tube, 0.5 mL of isopropyl alcohol was added, and the mixture was shaken by hand for 15 seconds. After reacting at room temperature for 8 minutes, the mixture was centrifuged at 13,000 rpm for 8 minutes at 4 ° C. The supernatant was discarded, and 0.5 mL of 75% alcohol was added thereto, followed by centrifugation at 4 ° C and 10,000 rpm for 5 minutes. Only the pellet was left, the supernatant was discarded, and 22 μL of deionized water was added to dissolve the pure RNA. The amount of RNA was quantified by measuring the absorbance at 260 nm using a spectrophotometer, and then, to synthesize cDNA, 3.5 μL of RNA, 3.5 μL of 10 × RT buffer (Invitrogen, # 18080-051), 2 μL of 50 μM oligo dT, 7 μL of 25 mM MgCl 2 , 3 μL of 10 mM dNTP, 1 μL of
그 결과, 도 2에 나타난 바와 같이, 인삼꽃 80MPa 가압 및 감압 추출물(실시예 3)이 무처리군(대조군), 열수 추출물(비교예 4), 및 대기압 하 일반 추출 공정에 의한 추출물(비교예 3)보다 항균 펩타이드 유전자인 hBD2, hBD3 및 서리아신 유전자의 발현을 증가시킴을 확인하였다. 따라서, 최적의 조건 하에서 가압 및 감압 추출된, 특정 함량의 진세노사이드를 포함하는 인삼꽃 추출물은 항균 펩타이드의 발현을 증가시킴으로써, 피부 장벽 기능을 강화하는 효과가 있음을 알 수 있었다. As a result, as shown in FIG. 2, the extracts of the ginseng flower 80 MPa pressurized and decompressed extracts (Example 3) in the untreated group (control group), hot water extract (Comparative Example 4) 3), the expression of the antimicrobial peptide genes hBD2, hBD3 and the frogasin gene was increased. Therefore, it was found that the ginseng flower extract containing a specific content of ginsenoside, under pressure and reduced pressure under optimum conditions, has an effect of enhancing the skin barrier function by increasing the expression of the antimicrobial peptide.
본 발명의 일 실시예에 따른 조성물의 제형예를 아래에서 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다Formulation examples of compositions according to one embodiment of the present invention are described below, but may be applied to various other formulations, which are not intended to be limiting but merely illustrative of the present invention
[제형예 1] 영양화장수[Formulation Example 1] Nutritional lotion
하기 표 7에 기재된 조성에 따라 통상적인 방법으로 영양화장수를 제조하였다.Nutrition lotion was prepared according to a conventional method according to the composition shown in Table 7 below.
[제형예 2] 영양로션[Formulation Example 2] Nutrition lotion
하기 표 8에 기재된 조성에 따라 통상적인 방법으로 영양로션을 제조할 수 있다.Nutrition lotions can be prepared in a conventional manner according to the composition shown in Table 8 below.
[제형예 3] 영양크림[Formulation Example 3] Nourishing cream
하기 표 9에 기재된 조성에 따라 통상적인 방법으로 영양크림을 제조할 수 있다.Nutrition creams can be prepared in a conventional manner according to the composition shown in Table 9 below.
[제형예 4] 헤어 팩[Formulation Example 4] Hair pack
하기 표 10에 기재된 조성에 따라 통상적인 방법으로 팩을 제조할 수 있다.The pack can be manufactured in a conventional manner according to the composition shown in Table 10 below.
[제형예 5] 연고[Formulation Example 5] Ointment
하기 표 11에 기재된 조성에 따라 통상적인 방법으로 연고를 제조할 수 있다.Ointment can be prepared by a conventional method according to the composition shown in Table 11 below.
[제형예 6] 국소 투여용 약제(패취제)의 제조[Formulation Example 6] Preparation of drug (patch) for topical administration
하기 표 12에 기재된 조성에 따라 통상적인 방법으로 국소 투여용 약제(패취제)를 제조하였다. Pharmaceutical preparations (patches) for topical administration were prepared in a conventional manner according to the compositions shown in Table 12 below.
[제형예 7] 산제의 제조[Formulation Example 7] Preparation of powders
실시예 3의 인삼꽃 추출물 2g2 g of the ginseng flower extract of Example 3
유당 1gLactose 1g
상기의 성분을 혼합한 후 기밀포에 충진하여 산제를 제조하였다.The above components were mixed and filled in airtight bags to prepare powders.
[제형예 8] 정제의 제조[Formulation Example 8] Preparation of tablets
실시예 3의 인삼꽃 추출물 100mgThe ginseng flower extract of Example 3 100 mg
옥수수전분 100mgCorn starch 100 mg
유당 100mgLactose 100mg
스테아린산 마그네슘 2mgMagnesium stearate 2 mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
[제형예 9] 캡슐제의 제조[Formulation Example 9] Preparation of capsules
실시예 3의 인삼꽃 추출물 100mgThe ginseng flower extract of Example 3 100 mg
옥수수전분 100mgCorn starch 100 mg
유 당 100mg100mg of milk
스테아린산 마그네슘 2mgMagnesium stearate 2 mg
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
[제형예 10] 환의 제조[Formulation Example 10] Production of pills
실시예 3의 인삼꽃 추출물 1g1 g of the ginseng flower extract of Example 3
유당 1.5gLactose 1.5g
글리세린 1gGlycerin 1 g
자일리톨 0.5gXylitol 0.5 g
상기의 성분을 혼합한 후, 통상의 방법에 따라 1환 당 4g이 되도록 제조하였다.After the above components were mixed, they were prepared to be 4 g per one ring by a conventional method.
[제형예 11] 과립의 제조[Formulation Example 11] Preparation of granules
실시예 3의 인삼꽃 추출물 150g150 g of the ginseng flower extract of Example 3
대두추출물 50mg Soybean extract 50mg
포도당 200mg200 mg of glucose
전분 600mgStarch 600mg
상기의 성분을 혼합한 후, 30% 에탄올 100mg을 첨가하여 섭씨 60 에서 건조하여 과립을 형성한 후 포에 충진하였다.After mixing the above components, 100 mg of 30% ethanol was added and the mixture was dried at 60 ° C to form granules, which were then filled in a capsule.
[제형예 12] 드링크제[Formulation Example 12]
실시예 3의 인삼꽃 추출물 50mg, 포도당 10g, 구연산 0.6g, 및 액상 올리고당 25g 혼합한 후 정제수 300ml를 가하여 각 병에 200ml씩 충진한다. 병에 충진한 후 130 에서 4~5 초간 살균하여 음료를 제조할 수 있다.After mixing 50 mg of the ginseng flower extract of Example 3, 10 g of glucose, 0.6 g of citric acid and 25 g of liquid oligosaccharide, 300 ml of purified water is added, and 200 ml of each is injected into each bottle. After filling the bottle, the beverage can be sterilized at 130 for 4 to 5 seconds.
[제형예 13] 캬라멜 제형[Formulation Example 13] Caramel formulation
실시예 3의 인삼꽃 추출물 50mg, 옥수수 시럽(corn syrup) 1.8g, 탈지우유 0.5g, 대두 레시틴 0.5g, 버터 0.6g, 식물성 경화유 0.4g, 설탕 1.4g, 마가린 0.58g, 및 식염 20mg을 혼합하여 캬라멜 성형을 할 수 있다.Mixed with 50 mg of the ginseng flower extract of Example 3, 1.8 g of corn syrup, 0.5 g of skim milk, 0.5 g of soybean lecithin, 0.6 g of butter, 0.4 g of vegetable cured oil, 1.4 g of sugar, 0.58 g of margarine, So that caramel molding can be performed.
Claims (17)
상기 인삼꽃 추출물은 추출 원료인 인삼꽃의 건조물이 100 중량부일 때 0.25 중량부 이상의 진세노사이드 Rb1, 0.20 중량부 이상의 진세노사이드 Rb2, 0.20 중량부 이상의 진세노사이드 Rc, 0.60 중량부 이상의 진세노사이드 Rd 및 0.25 중량부 이상의 진세노사이드 Rg1 중 하나 이상을 더 포함하는 피부 장벽 기능 강화용 조성물.The method according to claim 1,
The ginseng flower extract comprises 0.25 weight parts or more of ginsenoside Rb1, 0.20 weight parts or more of ginsenoside Rb2, 0.20 weight parts or more of ginsenoside Rc, 0.60 weight parts or more of ginsenoside Side Rd and at least 0.25 part by weight of ginsenoside Rg1.
상기 조성물은 항균 펩타이드 유전자의 발현을 증가시키는 것을 특징으로 하는, 피부 장벽 기능 강화용 조성물.The method according to claim 1,
Wherein the composition increases the expression of an antimicrobial peptide gene.
상기 항균 펩타이드 유전자는 인간 베타 디펜신 2(hBD2, human beta defensin 2), 인간 베타 디펜신 3(hBD3, human beta defensin 3) 및 서리아신(psoriasin)으로 이루어진 군으로부터 선택된 하나 이상인 것을 특징으로 하는, 피부 장벽 기능 강화용 조성물.The method of claim 3,
Wherein the antimicrobial peptide gene is at least one selected from the group consisting of human beta defensin 2, hBD3, human beta defensin 3 and psoriasin. A composition for enhancing skin barrier function.
상기 조성물은 상기 인삼꽃 추출물을 상기 조성물 전체 중량에 대하여 0.0001 내지 99 중량% 포함하는 것을 특징으로 하는, 피부 장벽 기능 강화용 조성물.The method according to claim 1,
Wherein the composition comprises 0.0001 to 99% by weight of the ginseng flower extract based on the total weight of the composition.
상기 인삼꽃 추출물은, 반복적인 가압 및 감압 추출물인, 피부 장벽 기능 강화용 조성물.The method according to claim 1,
Wherein the ginseng flower extract is a repetitive pressurized and decompressed extract.
상기 조성물은 약학 조성물인 것을 특징으로 하는, 조성물.7. The method according to any one of claims 1 to 6,
Wherein the composition is a pharmaceutical composition.
상기 조성물은 화장료 조성물인 것을 특징으로 하는, 조성물.7. The method according to any one of claims 1 to 6,
Wherein the composition is a cosmetic composition.
상기 조성물은 식품 조성물인 것을 특징으로 하는, 조성물.7. The method according to any one of claims 1 to 6,
Wherein the composition is a food composition.
인삼꽃에 1차 용매로서 물, 또는 알코올을 가한 후, 가압 및 감압 추출공정을 반복적으로 실시하여 1차 추출하는 단계;를 포함하는 것을 특징으로 하는, 조성물 제조방법.The method for producing a composition according to any one of claims 1 to 6,
A step of adding water or alcohol as a primary solvent to the ginseng flower, and then performing a primary extraction by repeatedly performing the pressure and decompression extraction steps.
상기 추출된 1차 추출물을 염소 함유 유기용매로 분획하고 염소 함유 유기용매 층을 제거한 다음 물 층을 다시 2차 용매인 알코올로 2차 추출하는 단계;를 추가적으로 포함하되, 상기 1차 용매가 알코올인 경우 분획 전에 1차 추출물을 물에 녹이는 것을 포함하는, 조성물 제조방법.11. The method according to claim 10,
Separating the extracted primary extract with a chlorine-containing organic solvent, removing the chlorine-containing organic solvent layer, and secondly extracting the water layer with an alcohol as a secondary solvent, wherein the primary solvent is an alcohol RTI ID = 0.0 > 1, < / RTI > the first extract is dissolved in water prior to fractionation.
상기 가압 및 감압 추출공정은 총 18 내지 30시간 동안 반복 실시하여 추출하는 것을 특징으로 하는, 조성물 제조방법.11. The method of claim 10,
Characterized in that the pressurized and reduced pressure extraction step is repeated for a total of 18 to 30 hours to extract.
상기 가압 및 감압 추출공정 시 추출 온도는 25 내지 35℃인 것을 특징으로 하는, 조성물 제조방법.11. The method of claim 10,
Wherein the extraction temperature in the pressurized and reduced pressure extraction step is 25 to 35 占 폚.
상기 가압 추출공정 시 압력은 60 내지 100 MPa, 감압 추출공정 시 압력은 대기압인 것을 특징으로 하는, 조성물 제조방법.11. The method of claim 10,
Wherein the pressure during the pressure extraction step is 60 to 100 MPa, and the pressure during the pressure extraction step is atmospheric pressure.
상기 조성물은 제10항 내지 제16항 중 어느 한 항에 의해 제조된 것인, 피부 장벽 기능 강화용 조성물.The method according to claim 1,
Wherein the composition is prepared by any one of claims 10 to 16.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170013027A KR102175469B1 (en) | 2017-01-26 | 2017-01-26 | Composition comprising ginseng flower extracts with enhanced ginsenoside content |
| CN201880008676.1A CN110234332A (en) | 2017-01-26 | 2018-01-19 | Composition comprising the extract of ginseng flower with increased ginsenoside amount as active constituent |
| PCT/KR2018/000880 WO2018139809A1 (en) | 2017-01-26 | 2018-01-19 | Composition containing, as active ingredient, ginseng flower extract having increased amount of ginsenosides |
| TW107102194A TW201831166A (en) | 2017-01-26 | 2018-01-22 | Composition comprising ginseng flower extracts with enhanced ginsenoside content |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170013027A KR102175469B1 (en) | 2017-01-26 | 2017-01-26 | Composition comprising ginseng flower extracts with enhanced ginsenoside content |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180088226A true KR20180088226A (en) | 2018-08-03 |
| KR102175469B1 KR102175469B1 (en) | 2020-11-06 |
Family
ID=62978052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170013027A Active KR102175469B1 (en) | 2017-01-26 | 2017-01-26 | Composition comprising ginseng flower extracts with enhanced ginsenoside content |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR102175469B1 (en) |
| CN (1) | CN110234332A (en) |
| TW (1) | TW201831166A (en) |
| WO (1) | WO2018139809A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210005459A (en) | 2019-07-06 | 2021-01-14 | 재단법인 경북바이오산업연구원 | Antimicrobial composition comprising the extract of flower bud of panax ginseng c. a. meyer |
| KR20230111465A (en) | 2022-01-18 | 2023-07-25 | 주식회사 한국인삼공사 | Composion Comprising Fraction of Ginseng Flower Extract |
| KR20230111466A (en) | 2022-01-18 | 2023-07-25 | 주식회사 한국인삼공사 | Cosmetic Composion for Skin Whitening Comprising Fraction of Ginseng Flower Extract |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130039470A (en) | 2011-10-12 | 2013-04-22 | (주)아모레퍼시픽 | Method for extracting ginseng extracts by steamming with rice |
| KR20130088283A (en) * | 2012-01-31 | 2013-08-08 | 대전대학교 산학협력단 | A composition comprising the dried flower bud powder of black panax ginseng for treating and preventing atopic disease |
| KR20150102360A (en) * | 2014-02-28 | 2015-09-07 | 주식회사 코리아나화장품 | Cosmetic composition containing an ginsenoside Rg3 reinforced extract of fermentative Ginseng flower(Panax ginseng C. A. Meyer) by Aureobasidium pullulans |
| KR20160070733A (en) * | 2008-06-13 | 2016-06-20 | (주)아모레퍼시픽 | Composition for applying to skin externally containing extract from flower of ginseng |
| KR20160086149A (en) * | 2015-01-09 | 2016-07-19 | (주)아모레퍼시픽 | Composition comprising ginseng extracts with enhanced ginsenoside content |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103479538B (en) * | 2008-06-13 | 2015-11-18 | 株式会社爱茉莉太平洋 | The Dermatologic preparation composition of the flower containing Radix Ginseng or the seed extract of Radix Ginseng |
| KR101860109B1 (en) * | 2011-09-22 | 2018-05-21 | (주)아모레퍼시픽 | Skin external composition containing floral ginsenoside |
-
2017
- 2017-01-26 KR KR1020170013027A patent/KR102175469B1/en active Active
-
2018
- 2018-01-19 CN CN201880008676.1A patent/CN110234332A/en active Pending
- 2018-01-19 WO PCT/KR2018/000880 patent/WO2018139809A1/en not_active Ceased
- 2018-01-22 TW TW107102194A patent/TW201831166A/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160070733A (en) * | 2008-06-13 | 2016-06-20 | (주)아모레퍼시픽 | Composition for applying to skin externally containing extract from flower of ginseng |
| KR20130039470A (en) | 2011-10-12 | 2013-04-22 | (주)아모레퍼시픽 | Method for extracting ginseng extracts by steamming with rice |
| KR20130088283A (en) * | 2012-01-31 | 2013-08-08 | 대전대학교 산학협력단 | A composition comprising the dried flower bud powder of black panax ginseng for treating and preventing atopic disease |
| KR20150102360A (en) * | 2014-02-28 | 2015-09-07 | 주식회사 코리아나화장품 | Cosmetic composition containing an ginsenoside Rg3 reinforced extract of fermentative Ginseng flower(Panax ginseng C. A. Meyer) by Aureobasidium pullulans |
| KR20160086149A (en) * | 2015-01-09 | 2016-07-19 | (주)아모레퍼시픽 | Composition comprising ginseng extracts with enhanced ginsenoside content |
Non-Patent Citations (1)
| Title |
|---|
| 김용이. '설화수, 자음생 업그레이드'. 네트위크신문 (2016.08.25.)* * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210005459A (en) | 2019-07-06 | 2021-01-14 | 재단법인 경북바이오산업연구원 | Antimicrobial composition comprising the extract of flower bud of panax ginseng c. a. meyer |
| KR20230111465A (en) | 2022-01-18 | 2023-07-25 | 주식회사 한국인삼공사 | Composion Comprising Fraction of Ginseng Flower Extract |
| KR20230111466A (en) | 2022-01-18 | 2023-07-25 | 주식회사 한국인삼공사 | Cosmetic Composion for Skin Whitening Comprising Fraction of Ginseng Flower Extract |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201831166A (en) | 2018-09-01 |
| CN110234332A (en) | 2019-09-13 |
| WO2018139809A1 (en) | 2018-08-02 |
| KR102175469B1 (en) | 2020-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102144318B1 (en) | Composition for enhancing immunity comprising Ginseng berry polysaccharide | |
| WO2005072684A1 (en) | Process for producing maca extract | |
| KR101889793B1 (en) | Composition for prevention of hair loss or for promoting hair growth comprising a marine animal fermentation | |
| KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
| KR101874462B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Schisandra chinensis leaf extract as effective component | |
| KR102070789B1 (en) | Composition for ameliorating or treating acne comprising Salvia plebeia extract and its fraction as effective component | |
| KR102175469B1 (en) | Composition comprising ginseng flower extracts with enhanced ginsenoside content | |
| KR102228257B1 (en) | Composition for anti-inflammation or anti-acne comprising extract of Immature Citrus Fruit, Curcuma longa and citrus blossom honey | |
| US7371416B2 (en) | Method for preparing processed ginseng to obtain increased amount of ginsenoside RG5 | |
| KR101125224B1 (en) | A composition for skin anti-aging comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient | |
| KR102371417B1 (en) | Composition for anti inflammation comprising extract of ginseng floral axis | |
| KR20180007834A (en) | Composition for cell regeneration comprising extract of ginseng floral axis | |
| KR102403229B1 (en) | Composition for improving skin containing Moringa extract and Opuntia humifusa extract thereof as an active ingredient | |
| KR102052523B1 (en) | A composition having anti-bacterial activity comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
| KR102114133B1 (en) | Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract | |
| KR102012170B1 (en) | Composition comprising extracts of banana, cherry, and walnut for anti-skin aging | |
| KR20150058698A (en) | Antioxidant composition containing purified bee venom | |
| KR102352017B1 (en) | Method of Preparing Concentrate of Deer Antlers | |
| KR20240076583A (en) | Cosmetic composition for anti-oxidative or anti-inflammatory comprising Citrus sinensis (L.) Osbeck Peel extract or fermentated extract thereof | |
| KR101529380B1 (en) | Composition including the compound derived from Polygonum multiflorum for prevention of hair loss or for promoting hair growth | |
| KR102746020B1 (en) | Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Artemisia argyi extract | |
| KR101935751B1 (en) | Antibiotic composition comprising plants extract | |
| TW201729825A (en) | Composition for promoting hair growth or preventing hair loss comprising extract of ginseng floral axis | |
| KR20160103547A (en) | Antioxidant composition containing purified bee venom | |
| KR101829514B1 (en) | Composition including the compound derived from Carpomitra costata for prevention of hair loss or for promoting hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20170126 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180710 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20170126 Comment text: Patent Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190812 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20200324 Patent event code: PE09021S02D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200924 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20201102 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20201103 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |